Most patients with small cell lung cancer (SCLC) have few effective treatment options. However, a small number of patients do something remarkable: their own immune systems recognize and attack the cancer, allowing them to live significantly longer. Understanding why that happens has led researchers at the USC Norris Comprehensive Cancer Center to a promising new strategy for treating the deadliest form of lung cancer, SCLC.
Although SCLC accounts for only about 15% of all lung cancer diagnoses, it affects roughly 30,000 to 35,000 people in the United States each year and is the most aggressive form of lung cancer. SCLC is strongly linked to cigarette smoking, with the majority of patients having a history of smoking. Unfortunately, over 90% of patients will not survive longer than five years. SCLC is characterized by its rapid growth, early spread, and high tendency to relapse, leaving patients with only modestly effective treatment options and little improvement in survival over the past several decades. New therapeutic approaches are urgently needed.
One clue has raised particular interest. About 15% of patients with SCLC develop antibodies against ELAVL4, a protein normally found in nerve cells but also produced by SCLC tumors. These patients survive significantly longer than those without this immune response, suggesting that their own immune system can recognize and fight the cancer. In rare instances, however, this response becomes so powerful that it mistakenly spreads to healthy nerve tissue as well. While in such patients the immune response can totally eradicate the cancer, it also causes serious neurological disease. These unusual patients reveal both the promise and the challenge of harnessing the immune system: how can its cancer-fighting ability be directed at tumors without harming healthy tissues?
Researchers in the Offringa Laboratory at the USC Norris Comprehensive Cancer Center have spent years investigating this phenomenon. By working backward to understand how these patients' immune systems recognized their tumors, they identified an unexpected clue: a form of protein damage known as isoaspartylation, found exclusively in the cancer. This small chemical change is like a kink in the protein’s molecular structure. It alters the normal ELAVL4 protein just enough so that the immune system recognizes it as something foreign that should be attacked. In other words, the damaged protein becomes a 'flag' that immune cells can see, triggering an anti-tumor response.
Harnessing the anti-ELAVL4 response builds on the same general principle that underpins modern cancer immunotherapy: helping the immune system recognize and eliminate cancer cells. However, instead of removing the immune system's brakes, as current “immune checkpoint inhibitor” therapies do, this approach teaches the immune system to recognize a unique feature (protein damage) in the tumor and launch a targeted attack. In a study recently submitted for publication, researchers in the Offringa lab found that vaccinating mice with the damaged form of ELAVL4 after standard chemotherapy significantly extends survival in a genetically-engineered mouse model of SCLC. The findings provide compelling preclinical evidence that teaching the immune system to recognize this damaged protein may represent an entirely new therapeutic strategy for this devastating disease.
The next phase of the research is already underway. The team is developing so-called “monoclonal antibodies”, targeted immune molecules that specifically recognize the damaged version of ELAVL4. This may lay the groundwork for the development of future diagnostic and treatment tools. What began as an unexpected clinical observation in a small group of patients has grown into a promising translational research program, offering hope that the immune system itself may reveal a new path toward treating one of the most aggressive forms of lung cancer.